BioLight Announces U.S. Patent Approval for its Formulation of Latanoprost in its Proprietary Controlled Release Insert for the Treatment of Glaucoma

BioLight announces that ViSci, its wholly owned subsidiary, has been informed that a patent number 8,722,739 covering the proprietary formulation of Latanoprost,the medication contained in its controlled release insert for the treatment of Glaucoma, has been granted by the U.S. Patent and Trademark Office. The patent is intended to protect, inter alia, the chemical structure of the active ingredient for the treatment of glaucoma. The patent is also covering the release of the active ingredient from the Eye-D® subconjunctival insert and its use in treating elevated intra-ocular pressure in patients with glaucoma and ocular hypertension. The patent and its registration will be in effect at least until April 2030.

Link to the complete article

Link to Newsroom

Comments are closed